RRC ID |
58779
|
著者 |
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H.
|
タイトル |
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
|
ジャーナル |
Cancer Immunol Immunother
|
Abstract |
Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial-mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal phosphorylation is a hallmark of malignancy, targeting phosphorylated vimentin is a feasible approach for the treatment of metastatic tumors while sparing non-tumor cells. Recent evidence has revealed that both CD8 cytotoxic T lymphocytes (CTLs) and also CD4 helper T lymphocytes (HTLs) can distinguish post-translationally modified antigens from normal antigens. Here, we showed that the expression of phosphorylated vimentin was upregulated in metastatic sites of CRC. We also showed that a chemotherapeutic reagent augmented the expression of phosphorylated vimentin. The novel phosphorylated helper peptide epitopes from vimentin could elicit a sufficient T cell response. Notably, precursor lymphocytes that specifically reacted to these phosphorylated vimentin-derived peptides were detected in CRC patients. These results suggest that immunotherapy targeting phosphorylated vimentin could be promising for metastatic CRC patients.
|
巻・号 |
69(6)
|
ページ |
989-999
|
公開日 |
2020-6-1
|
DOI |
10.1007/s00262-020-02524-9
|
PII |
10.1007/s00262-020-02524-9
|
PMID |
32086539
|
MeSH |
Adult
Aged
Cell Line
Cell Line, Tumor
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
Female
Humans
Immunotherapy / methods*
Male
Middle Aged
Neoplasm Metastasis
Vimentin / pharmacology
Vimentin / therapeutic use*
|
IF |
5.442
|
引用数 |
0
|
リソース情報 |
ヒト・動物細胞 |
Sa3(RCB0980)
LU65(RCB1967) |